*Alphabetical order by first name
Alnylam Pharmaceuticals
TBD
Duke University
Preclinical and Clinical Development of Anticoagulant and Thrombolytic Aptamers and Reversal Agents
Novo Nordisk
Harnessing the Promise of RNA Therapeutics
Tokyo University of Science
Development of New Molecular Technologies for siRNA Therapeutics
Nagoya University
Chemical Synthesis and Engineering of mRNA for Next-Generation Nucleic Acid Therapeutics
Institute of Science Tokyo
Potent and Specific siRNA Design: From Sequence Rules to Structure-Guided Precision Therapeutics
Ractigen Therapeutics
RNAa: From Bench to Bedside—A 20-Year Journey
Dyne Therapeutics
TBD
The University of Hong Kong
High-Resolution RNA Knockdown Profiles of Small RNA and Cas13 Systems
Peking University
TBD
Xenolis Pte Ltd
Novel DNA Modality: Genetic Alphabet Expansion
Luxna Biotech
Addressing key challenges in Oligonucleotide Therapeutics with Luxna Xeno Nucleic Acid (XNA) Technologies
Wave Life Sciences
From Chiral Monomers to Stereopure Oligonucleotides: Synthesis and NMR Characterization
Ionis Pharmaceuticals
Zilganersen in Alexander Disease: Translational Pharmacology, CNS Delivery, and Intrathecal Safety
Thomas Rupp Consulting UG
The Impurity Puzzle: Connecting Process, Quality, and Regulatory Strategy
Rasayan Inc.
TBD